Medline Inc. MDLN
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -11.81%
- 1 year
- -9.66%
5D -1.65 (-4.27%)
- Market cap
- 48.75B
- Revenue (ttm)
- 30.68B
- Profit margin
- 1.85%
- EPS (ttm)
- 0.44
- Shares out
- 878.66M
- P/E ratio
- 84.18
- Forward P/E
- 23.98
- YTD return
- -11.81%
- 1-year return
- -9.66%
- Volume
- 8.19M
- Avg volume
- 9.51M
- Open
- 37.65
- Previous close
- 37.84
- Day's range
- 36.94 – 38.37
- 52-week range
- 31.37 – 50.88
- Analysts
- Buy
- Price target
- 45.61 (+23.1%)
- Earnings date
- Feb 24, 2027
Key statistics
- 50-day average
- 35.60
- 200-day average
- 39.25
- Enterprise value
- 49.86B
- Price / sales
- 1.59
- Price / book
- 2.76
- Revenue growth
- 10.40%
- Free cash flow
- 1.39B
- Total cash
- 3.62B
- Total debt
- 12.65B
- Return on equity
- 4.84%
- Short % of float
- 8.95%
Fundamental scorecard
9 of 25 checks passed on MDLN’s reported financials
9of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 1 of 5
- Dividend 3 of 5
Statements to Sep 26, 2026.
Analyst view
Consensus: buy
- Target (low)
- 34.00
- Target (mean)
- 45.61
- Target (high)
- 55.00
- Strong buy6
- Buy14
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.39609.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 26, 2026 | 0.39 | — | — | — |
| Nov 4, 2026 | Sep 26, 2026 | 0.3432 | 0.44 | +0.10 | +28.21% |
| Aug 5, 2026 | Jun 27, 2026 | 0.3524 | 0.50 | +0.15 | +41.88% |
| May 6, 2026 | Mar 31, 2026 | 0.2952 | 0.33 | +0.03 | +11.79% |
| Feb 25, 2026 | Dec 31, 2025 | 0.2381 | 0.2247 | -0.01 | -5.63% |
| Nov 4, 2025 | Sep 30, 2025 | — | 0.31 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2026 | Barclays | main | Overweight | Overweight |
| Nov 5, 2026 | UBS | main | Buy | Buy |
| Nov 5, 2026 | Citigroup | main | Buy | Buy |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 5, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Nov 5, 2026 | BTIG | reit | Buy | Buy |
About Medline Inc.
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- medline.com
News
Barclays Maintains Overweight on Medline, Raises Price Target to $45
Medline launches right-sized Ranpak packaging solutions in two key distribution centers
MDLN Investigation: Medline is being Investigated for Securities Fraud Following Product Quality Issues – Contact BFA Law if You Lost Money
Medline Inc. announces pricing of secondary offering of Class A common stock
3,741,918 Medline $MDLN Shares Sold by Bessemer Group Inc.
Medline Inc. announces launch of secondary offering of Class A common stock Medline Files Prospectus For Secondary Offering of 60M Shares On Behalf Of Selling Shareholders; To Repurchase $200M Of Stock From Selling Shareholders At Assumed Price Of $39.47/Share
UBS Maintains Buy on Medline, Raises Price Target to $49
Citigroup Maintains Buy on Medline, Raises Price Target to $47
Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46
Your note
Sign in to keep a note on MDLN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOYLE JAMES M. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 11, 2026 | 0 |
| BX MOZART ML-1 HOLDCO L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Nov 17, 2026 | 0 |
| BX MOZART ML-2 HOLDCO L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 27, 2026 | 0 |
| CARLYLE GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 9, 2026 | 0 |
| GIC PRIVATE LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 7, 2026 | 0 |
| HELLMAN & FRIEDMAN CAPITAL PARTNERS X PARALLEL, L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | May 27, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Carlyle Group Inc. | 21.29% | 187,083,713 | 6.93B | Sep 29, 2026 |
| Blackstone Inc | 11.58% | 101,791,008 | 3.77B | Sep 29, 2026 |
| H&f Corporate Investors X, Ltd. | 8.07% | 70,874,326 | 2.63B | Sep 29, 2026 |
| Capital Research Global Investors | 5.44% | 47,756,528 | 1.77B | Sep 29, 2026 |
| FMR, LLC | 5.06% | 44,424,934 | 1.65B | Sep 29, 2026 |
| Invesco Ltd. | 4.60% | 40,435,265 | 1.50B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Amcap Fund | 2.14% | 18,780,959 | 695.65M | Sep 29, 2026 |
| Fidelity Contrafund | 1.66% | 14,598,531 | 540.73M | Sep 29, 2026 |
| Growth Fund of America | 1.58% | 13,853,297 | 513.13M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41% | 12,406,857 | 459.55M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 0.96% | 8,466,394 | 313.60M | Jun 29, 2026 |
| MFS SERIES TRUST I-MFS Value Fund | 0.78% | 6,853,598 | 253.86M | Aug 30, 2026 |
